Immatics Reports Positive Phase 1 Data for TCR Bispecific Therapies in Solid Tumors
Immatics NV has reported positive Phase 1 data for its TCR Bispecific candidates, IMA402 and IMA401, in solid tumors. Both candidates showed favorable tolerability and durable responses in heavily pre-treated patients. IMA402 achieved a confirmed overall response rate of 30%, while IMA401 had rates of 25% in head and neck cancer. Median progression-free survival for IMA402 was 4.8 months, with a one-year overall survival rate of 94%. Immatics plans to advance IMA402 into Phase 1b studies, focusing on melanoma and gynecologic cancers.
Immatics NV has announced the achievement of clinical proof-of-concept for its next-generation TCR Bispecific (TCER®) candidates, IMA402 (PRAME Bispecific) and IMA401 (MAGEA4/8 Bispecific), in patients with solid tumors. The company reported that both candidates demonstrated favorable tolerability and durable responses in heavily pre-treated, last-line patients. Specifically, IMA402 achieved a confirmed overall response rate (cORR) of 30% across all indications, including 29% in melanoma and responses in ovarian carcinoma, while IMA401 showed cORRs of 25% in head and neck cancer and 29% in melanoma. Median progression-free survival (PFS) for IMA402 was 4.8 months, and the one-year overall survival rate was 94%. Immatics plans to advance IMA402 into Phase 1b dose expansion studies as a monotherapy and in combination with an immune checkpoint inhibitor, focusing on melanoma and gynecologic cancers. The company announced that these results were presented during a conference call and webcast on November 12. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001138392-en) on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
